Factor V Leiden Mutation and Implantation Failure
NCT00194350 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 399
Last updated 2011-08-09
Summary
The purpose of this study is to determine whether inherited thrombophilias (tendency toward blood clotting) increase the risk of failure of the embryo to implant in IVF. The specific condition to be studied is the presence or absence of the Leiden mutation of the Factor V gene.
Conditions
Interventions
- PROCEDURE
-
Test for Factor V Leiden gene mutation
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Kurt T Barnhart, MD, MSCE · University of Pennsylvania
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-09-30
- Completion
- 2005-08-31
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
NCT03405337 ·Status: COMPLETED
-
Clinical Trial on Treatment of Intraventricular Hemorrhage
NCT00650858 ·Status: COMPLETED ·Phase: PHASE2
-
Patient Interview Study to Explore the Impact of Gene Therapy in Hemophilia A & B
NCT06634836 ·Status: WITHDRAWN
-
Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia
NCT01439971 ·Status: COMPLETED ·Phase: PHASE1
-
Liver Biopsy Following Gene Therapy For Hemophilia
NCT05932914 ·Status: NOT_YET_RECRUITING
-
A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture
NCT02402829 ·Status: TERMINATED
-
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
NCT00989196 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
NCT02396342 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Evaluating Inhibitor Specificity in Hemophilia A
NCT00151385 ·Status: WITHDRAWN ·Phase: PHASE4
-
Liver Biopsy In Haemophilia Gene Therapy
NCT04817462 ·Status: RECRUITING ·Phase: NA
-
Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
NCT01571934 ·Status: COMPLETED
-
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00945906 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating ReFacto in Hemophilia A
NCT00038909 ·Status: COMPLETED ·Phase: NA
-
Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A
NCT01405742 ·Status: TERMINATED ·Phase: PHASE3
-
Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
NCT03876301 ·Status: COMPLETED
-
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
NCT00178607 ·Status: COMPLETED
-
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
NCT01708564 ·Status: COMPLETED ·Phase: PHASE1
-
The Proteins of the Contact Activation System
NCT02785718 ·Status: UNKNOWN ·Phase: NA
-
Lentiviral FVIII Gene Therapy
NCT03217032 ·Status: RECRUITING ·Phase: PHASE1
-
Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
NCT00038935 ·Status: COMPLETED ·Phase: PHASE3
-
Quality of Life Study of Helixate NexGen
NCT01053715 ·Status: COMPLETED
-
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
NCT02396862 ·Status: COMPLETED
-
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
NCT03996486 ·Status: WITHDRAWN ·Phase: PHASE1
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
NCT05568719 ·Status: RECRUITING ·Phase: PHASE3
-
Study Evaluating ReFacto AF in Severe Hemophilia A
NCT00037544 ·Status: COMPLETED ·Phase: PHASE3